The Shieldin complex mediates 53BP1-dependent DNA repair

Abstract53BP1 is a chromatin-binding protein that regulates the repair of DNA double-strand breaks by suppressing the nucleolytic resection of DNA termini1,2. This function of 53BP1 requires interactions with PTIP3 and RIF14–9, the latter of which recruits REV7 (also known as MAD2L2) to break sites10,11. How 53BP1-pathway proteins shield DNA ends is currently unknown, but there are two models that provide the best potential explanation of their action. In one model the 53BP1 complex strengthens the nucleosomal barrier to end-resection nucleases12,13, and in the other 53BP1 recruits effector proteins with end-protection activity. Here we identify a 53BP1 effector complex, shieldin, that includes C20orf196 (also known as SHLD1), FAM35A (SHLD2), CTC-534A2.2 (SHLD3) and REV7. Shieldin localizes to double-strand-break sites in a 53BP1- and RIF1-dependent manner, and its SHLD2 subunit binds to single-stranded DNA via OB-fold domains that are analogous to those of RPA1 and POT1. Loss of shieldin impairs non-homologous end-joining, leads to defective immunoglobulin class switching and causes hyper-resection. Mutations in genes that encode shieldin subunits also cause resistance to poly(ADP-ribose) polymerase inhibition in BRCA1-deficient cells and tumours, owing to restoration of homologous recombination. Finally, we show that binding of single-stranded DNA by SHLD2 is critical for shieldin function, consistent with a model in which shieldin protects DNA ends to mediate 53BP1-dependent DNA repair.The 53BP1 effector complex shieldin is involved in non-homologous end-joining and immunoglobulin class switching, and acts to protect DNA ends to facilitate the repair of DNA by 53BP1.

[1]  Michelle Brault,et al.  Novel fluorescent genome editing reporters for monitoring DNA repair pathway utilization at endonuclease-induced breaks , 2013, Nucleic acids research.

[2]  Grant W. Brown,et al.  HELB Is a Feedback Inhibitor of DNA End Resection. , 2016, Molecular cell.

[3]  Hyungwon Choi,et al.  SAINT: Probabilistic Scoring of Affinity Purification - Mass Spectrometry Data , 2010, Nature Methods.

[4]  Peter Bouwman,et al.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.

[5]  R. Greenberg,et al.  Acetylation Limits 53BP1 Association with Damaged Chromatin to Promote Homologous Recombination , 2012, Nature Structural &Molecular Biology.

[6]  Jeremy M. Stark,et al.  53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.

[7]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[8]  J. Jonkers,et al.  The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells , 2018, Cell reports.

[9]  T. Honjo,et al.  High frequency class switching of an IgM+ B lymphoma clone CH12F3 to IgA+ cells. , 1996, International immunology.

[10]  D. Adams,et al.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.

[11]  Michal Zimmermann,et al.  53BP1/Rif1/Shieldin counteract DSB resection through CST/Polα-dependent fill-in , 2018, Nature.

[12]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[13]  P. Baumann,et al.  Pot1 and telomere maintenance , 2010, FEBS letters.

[14]  Natalie I. Tasman,et al.  iProphet: Multi-level Integrative Analysis of Shotgun Proteomic Data Improves Peptide and Protein Identification Rates and Error Estimates* , 2011, Molecular & Cellular Proteomics.

[15]  D. Durocher,et al.  High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.

[16]  F. Alt,et al.  53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions , 2013, Cell.

[17]  J. Rouse,et al.  Phospho-epitope binding by the BRCT domains of hPTIP controls multiple aspects of the cellular response to DNA damage , 2007, Nucleic acids research.

[18]  D. Durocher,et al.  53BP1 is a reader of the DNA damage-induced H2A Lys15 ubiquitin mark , 2013, Nature.

[19]  H. Clevers,et al.  Controlled gene expression in primary Lgr5 organoid cultures , 2011, Nature Methods.

[20]  N. Pavletich,et al.  Structure and conformational change of a replication protein A heterotrimer bound to ssDNA. , 2012, Genes & development.

[21]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[22]  Tony Pawson,et al.  OpenFreezer: a reagent information management software system , 2011, Nature Methods.

[23]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[24]  P. Sung,et al.  NUCLEOSOME DYNAMICS REGULATE DNA PROCESSING , 2013, Nature Structural &Molecular Biology.

[25]  Y. Murakumo,et al.  Overlapping in short motif sequences for binding to human REV7 and MAD2 proteins , 2010, Genes to cells : devoted to molecular & cellular mechanisms.

[26]  Stéphanie Panier,et al.  Double-strand break repair: 53BP1 comes into focus , 2013, Nature Reviews Molecular Cell Biology.

[27]  Amber L. Couzens,et al.  The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.

[28]  R. Durbin,et al.  Systematic Analysis of Human Protein Complexes Identifies Chromosome Segregation Proteins , 2010, Science.

[29]  Adam P. Rosebrock,et al.  A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. , 2013, Molecular cell.

[30]  Guomin Liu,et al.  SAINTexpress: improvements and additional features in Significance Analysis of INTeractome software. , 2014, Journal of proteomics.

[31]  A. Ashworth,et al.  Modeling Therapy Resistance in BRCA1/2-Mutant Cancers , 2017, Molecular Cancer Therapeutics.

[32]  D. Durocher,et al.  MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end-resection , 2015, Nature.

[33]  Michel C. Nussenzweig,et al.  Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching , 2013, Science.

[34]  Facundo D. Batista,et al.  RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection , 2013, Molecular cell.

[35]  Julio Saez-Rodriguez,et al.  A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia , 2016, Cell reports.

[36]  D. Durocher,et al.  Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens , 2017, G3: Genes, Genomes, Genetics.

[37]  Lin Feng,et al.  RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair* , 2013, The Journal of Biological Chemistry.

[38]  H. van Attikum,et al.  PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining , 2016, Molecular cell.

[39]  Daniel Durocher,et al.  The control of DNA repair by the cell cycle , 2016, Nature Cell Biology.

[40]  J. Peterse,et al.  Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer , 2007, Proceedings of the National Academy of Sciences.

[41]  Martin A. M. Reijns,et al.  CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.

[42]  A. Hollestelle,et al.  BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. , 2006, Cancer research.

[43]  Tony Pawson,et al.  ProHits: an integrated software platform for mass spectrometry-based interaction proteomics , 2010, Nature Biotechnology.

[44]  Jun S. Liu,et al.  MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.

[45]  S. B. Buonomo,et al.  53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection , 2013, Science.

[46]  L. Zou,et al.  RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response , 2014, Cell Research.

[47]  D. Durocher,et al.  Identifying drug-gene interactions from CRISPR knockout screens with drugZ , 2017, bioRxiv.

[48]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[49]  Hans Clevers,et al.  BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance , 2017, Nature Methods.

[50]  Peter Bouwman,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[51]  A. Ashworth,et al.  Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance , 2017, bioRxiv.